In addition, platinum-based chemotherapeutic agents such as oxaliplatin had been reported to be substrates for SLC22A1-3 [88], and high expression of SLC22A3 promoted the uptake of oxaliplatin, which accumulated more platinum and exerted stronger toxic effects on cancer cells [89]. Here, SLC22A3 is linked to cancer.